Company profile
Formycon AG
FYB · Frankfurt (Formycon's official investor-relations materials identify Formycon AG as a Frankfurt-listed company (FYB), while the persisted CT.gov and GLEIF records establish the legal entity. Sources: https://clinicaltrials.gov/study/NCT06708624 ; https://api.gleif.org/api/v1/lei-records/39120005TZ76GQOY8Z19 Entity resolved by asset-pipeline-v2.)
Public Market Listing
Live quotes, historical charts, and market capitalization for Formycon AG are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Aflibercept(Eylea) | Approved | VEGF-A · VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Protein / enzyme therapeutic | Age-Related Macular Degeneration |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.